REVVITY, INC.
Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.
Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.
Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.
Over the past 7 days, alphai's AI scored 8 news stories mentioning RVTY (REVVITY, INC.). Coverage has skewed bullish: 7 bullish, 1 neutral, and 0 bearish.
Recent RVTY coverage spans earnings, technology and financial news.
In the last 30 days, RVTY insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($9K). The most active reporter was Gonzales Anita, Vice President and CAO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance raise plus stronger backlog and AI-instrument demand likely supports RVTY estimates, while Signals software decline and Life Sciences softness remain near-term risks.
Raised FY organic growth and 2H Signals software expectations, with margin/EPS support from a $16M tariff-refund benefit and leverage reduction plan.
The earnings and guidance beat likely supports near-term upside momentum, but the stock is already near its 52-week high.
Diagnostics strength and margin expansion drove the beat, while Life Sciences organic weakness and tariff-refund contribution are key swing factors for near-term sentiment.
Upward guidance revision is a direct fundamental catalyst that can re-rate near-term expectations and sentiment.
alphai scores every news story that mentions RVTY with an AI model for sentiment and relevance, and aggregates insider trades from REVVITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.
6 min readRevvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.
6 min readRevvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.
4 min readRevvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.
6 min readRevvity, Inc. (RVTY) revised higher annual guidance, increasing its fiscal 2026 outlook for pro forma adjusted earnings and related revenue expectations, according to the company. A separate report said Revvity’s Q2 bottom line fell to $51.820 million, or $0.47 per share, versus the prior year period.
2 min readRevvity (NYSE: RVTY) reported Q2 CY2026 results. Revenue rose 7.2% year on year to $729.7 million, exceeding analysts’ estimates by 3.2%. Full-year revenue guidance is $2.85 billion at the midpoint, 0.5% above estimates. Non-GAAP EPS was $1.41, 15.9% above consensus.
4 min readREVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document FOR IMMEDIATE RELEASE August 4, 2026 Revvity Announces Financial Results for the Second Quarter of 2026 • Revenue of $730 million; pro forma revenue of $711 million; 4% pro forma revenue growth; 3% pro forma organic revenue growth
6 min readRevvity (NYSE: RVTY) will report earnings Tuesday before the bell. The company missed last quarter’s revenue expectations with $686.9 million, up 9.3% YoY, and also fell short on full-year revenue guidance and EPS. For the upcoming quarter, analysts expect 3.9% YoY revenue growth. The average analyst price target is $117.13 vs $112.52.
3 min readRevvity, Inc. said it is developing the T-SPOT A201, a next-generation high-throughput automated platform for latent TB testing. The company targets a second-half 2027 launch, aiming to match T-SPOT.TB performance while improving workflow efficiency and scalability for large labs. Revvity shares rose 2.4% after the announcement.
7 min readS&P Global Ratings changed Revvity Inc.’s (NYSE:RVTY) outlook to stable from negative while keeping its BBB issuer credit rating. It cited adjusted leverage held at or below 3x despite share repurchases, expecting leverage of 2.7x by end-2026 and 2.4x in 2027. It forecasts free operating cash flow above $500M and organic revenue growth of 3.5% to 4.5% in 2026-27.
3 min read
